Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with 18F-FAHA
暂无分享,去创建一个
Tatsuya Higashi | Karl Herholz | Shinya Kagawa | Rainer Hinz | Mei Tian | Nobuyoshi Fukumitsu | Ashutosh Pal | Rajesh Uthamanthil | Hirotaka Onoe | Ryuichi Nishii | Hsien-Hsien Yeh | Daniel Young | Alexander Shavrin | Uday Mukhapadhyay | Leo G. Flores | Julius Balatoni | Suren Soghomonyan | Hwan J. Jeong | James N. Jackson | Hiroshi Mizuma | Mian M. Alauddin | William P. Tong | Juri G. Gelovani | H. Onoe | K. Herholz | R. Hinz | T. Higashi | R. Nishii | Hwan-Jeong Jeong | J. Gelovani | L. Flores | S. Kagawa | J. Balatoni | M. Alauddin | W. Tong | N. Fukumitsu | H. Mizuma | M. Tian | S. Soghomonyan | A. Pal | H. Yeh | Daniel Young | R. Uthamanthil | James Jackson | Uday Mukhapadhyay | A. Shavrin
[1] T. Abel,et al. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. , 2008, Current opinion in pharmacology.
[2] N. Volkow,et al. Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography , 2010 .
[3] S. Petri,et al. Differential Histone Deacetylase mRNA Expression Patterns in Amyotrophic Lateral Sclerosis , 2010, Journal of neuropathology and experimental neurology.
[4] E. Thomas. Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors , 2009, Molecular Neurobiology.
[5] U. Koch,et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases , 2007, Proceedings of the National Academy of Sciences.
[6] M. K. Meintzer,et al. Inactivation of the Myocyte Enhancer Factor-2 Repressor Histone Deacetylase-5 by Endogenous Ca2//Calmodulin-dependent Kinase II Promotes Depolarization-mediated Cerebellar Granule Neuron Survival* , 2003, Journal of Biological Chemistry.
[7] W. Bornmann,et al. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy , 2006, Molecular Cancer Therapeutics.
[8] Eric J. Nestler,et al. Epigenetic regulation in psychiatric disorders , 2007, Nature Reviews Neuroscience.
[9] L. Heidmets,et al. Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice , 2007, Behavioural Brain Research.
[10] L. Crepaldi,et al. Chromatin learns to behave , 2009, Epigenetics.
[11] J. Cha,et al. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). , 2006, Current Alzheimer research.
[12] D. Clarke. Fluoroacetate and fluorocitrate: Mechanism of action , 1991, Neurochemical Research.
[13] Dimitris Thanos,et al. Integration of Long-Term-Memory-Related Synaptic Plasticity Involves Bidirectional Regulation of Gene Expression and Chromatin Structure , 2002, Cell.
[14] R. Ferrante,et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice , 2005, Journal of neurochemistry.
[15] A. Contestabile,et al. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. , 2009, Current molecular pharmacology.
[16] E. Nestler,et al. Epigenetics in the Nervous System , 2008, The Journal of Neuroscience.
[17] A. Chiarugi,et al. Pharmacological Inhibition of Histone Deacetylases by Suberoylanilide Hydroxamic Acid Specifically Alters Gene Expression and Reduces Ischemic Injury in the Mouse Brain , 2006, Molecular Pharmacology.
[18] A. Barco,et al. Selective Boosting of Transcriptional and Behavioral Responses to Drugs of Abuse by Histone Deacetylase Inhibition , 2009, Neuropsychopharmacology.
[19] N. Volkow,et al. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. , 2010, ACS chemical neuroscience.
[20] G. Bates,et al. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders , 2006, Nature Reviews Neuroscience.
[21] R. De Francesco,et al. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. , 2008, Bioorganic & medicinal chemistry letters.
[22] H. L. Carrell,et al. Fluorocitrate Inhibition of Aconitase: Relative Configuration of Inhibitory Isomer by X-ray Crystallography , 1970, Science.
[23] L. Tsai,et al. Targeting the correct HDAC(s) to treat cognitive disorders. , 2010, Trends in pharmacological sciences.
[24] E. Nestler,et al. Histone acetylation in drug addiction. , 2009, Seminars in cell & developmental biology.
[25] Jason S. Lewis,et al. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. , 2011, Nuclear medicine and biology.
[26] L. Thompson,et al. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders , 2008, Nature Reviews Drug Discovery.
[27] C. Stout,et al. The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[28] Scott J. Russo,et al. Chromatin Remodeling Is a Key Mechanism Underlying Cocaine-Induced Plasticity in Striatum , 2005, Neuron.
[29] T. Yao,et al. Intracellular Trafficking of Histone Deacetylase 4 Regulates Neuronal Cell Death , 2005, The Journal of Neuroscience.
[30] A. Mai,et al. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. , 2009, Current pharmaceutical design.
[31] O. Mawlawi,et al. Whole-Body Biodistribution Kinetics, Metabolism, and Radiation Dosimetry Estimates of 18F-PEG6-IPQA in Nonhuman Primates , 2011, The Journal of Nuclear Medicine.
[32] Luc Pellerin,et al. Monocarboxylate transporters in the central nervous system: distribution, regulation and function , 2005, Journal of neurochemistry.
[33] S. Minucci,et al. New method to detect histone acetylation levels by flow cytometry , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[34] P. Casaccia,et al. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. , 2010, Pharmacological research.
[35] J. A. Hendricks,et al. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). , 2011, Journal of medicinal chemistry.
[36] J. Gelovani,et al. Radiosynthesis of 6-([18F]fluoroacetamido)-1-hexanoic-anilide ([18F]FAHA) for PET imaging of histone deacetylase (HDAC) , 2006 .
[37] Guanghua Xiao,et al. Histone Deacetylase 5 Epigenetically Controls Behavioral Adaptations to Chronic Emotional Stimuli , 2007, Neuron.
[38] Xin-Min Li,et al. Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats , 2003, Brain Research.
[39] C. Allis,et al. Translating the Histone Code , 2001, Science.
[40] L. Bidaut,et al. Pharmacokinetics, Metabolism, Biodistribution, Radiation Dosimetry, and Toxicology of 18F-Fluoroacetate (18F-FACE) in Non-human Primates , 2012, Molecular Imaging and Biology.
[41] H. Bading,et al. Neuronal activity‐dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5 , 2003, Journal of neurochemistry.
[42] C. Pérez-Plasencia,et al. Molecular Cancer Histone Acetylation and Histone Deacetylase Activity of Magnesium Valproate in Tumor and Peripheral Blood of Patients with Cervical Cancer. a Phase I Study , 2005 .
[43] B. Morrison,et al. Class IIA HDACs in the regulation of neurodegeneration. , 2008, Frontiers in bioscience : a journal and virtual library.
[44] E. Nestler,et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action , 2006, Nature Neuroscience.
[45] F. Bloom,et al. Distribution of histone deacetylases 1–11 in the rat brain , 2007, Journal of Molecular Neuroscience.
[46] L. Schwartz,et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] R. Ugale,et al. Brain Chromatin Remodeling: A Novel Mechanism of Alcoholism , 2008, The Journal of Neuroscience.
[48] F. Fonnum,et al. Use of fluorocitrate and fluoroacetate in the study of brain metabolism , 1997, Glia.
[49] J. Keil,et al. Sodium fluoroacetate poisoning. , 1975, American journal of diseases of children.
[50] Richard O Jenkins,et al. Toxicology of fluoroacetate: a review, with possible directions for therapy research , 2006, Journal of applied toxicology : JAT.
[51] N. Volkow,et al. Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. , 2009, Nuclear medicine and biology.
[52] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[53] R. Peters,et al. Biochemistry of fluoroacetate poisoning. The isolation and some properties of the fluorotricarboxylic acid inhibitor of citrate metabolism , 1953, Proceedings of the Royal Society of London. Series B - Biological Sciences.